Gabra2 is a genetic modifier of Scn8a encephalopathy in the mouse*

Wenxi Yu,Sophie F. Hill,James G. Xenakis,Fernando Pardo‐Manuel de Villena,Jacy L. Wagnon,Miriam H. Meisler
DOI: https://doi.org/10.1111/epi.16741
IF: 6.74
2020-11-02
Epilepsia
Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Objective</h3><p><i>SCN8A</i> encephalopathy is a developmental epileptic encephalopathy typically caused by de novo gain‐of‐function mutations in Na<sub>v</sub>1.6. Severely affected individuals exhibit refractory seizures, developmental delay, cognitive disabilities, movement disorders, and elevated risk of sudden death. Patients with the identical <i>SCN8A</i> variant can differ in clinical course, suggesting a role for modifier genes in determining disease severity. The identification of genetic modifiers contributes to understanding disease pathogenesis and suggesting therapeutic interventions. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>We generated F1 and F2 crosses between inbred mouse strains and mice carrying the human pathogenic variants <i>SCN8A</i>‐R1872W and <i>SCN8A</i>‐N1768D. Quantitative trait locus (QTL) analysis of seizure‐related phenotypes was used for chromosomal mapping of modifier loci. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>In an F2 cross between strain SJL/J and C57BL/6J mice carrying the patient mutation R1872W, we identified a major QTL on chromosome 5 containing the <i>Gabra2</i> gene. Strain C57BL/6J carries a splice site mutation that reduces expression of <i>Gabra2</i>, encoding the α2 subunit of the aminobutyric acid type A receptor. The protective wild‐type allele of <i>Gabra2</i> from strain SJL/J delays the age at seizure onset and extends life span of the <i>Scn8a</i> mutant mice. Additional <i>Scn8a</i> modifiers were observed in the F2 cross and in an F1 cross with strain C3HeB/FeJ. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Significance</h3><p>These studies demonstrate that the SJL/J strain carries multiple modifiers with protective effects against seizures induced by gain‐of‐function mutations in <i>Scn8a</i>. Homozygosity for the hypomorphic variant of <i>Gabra2</i> in strain C57BL/6J is associated with early seizure onset and short life span. <i>GABRA2</i> is a potential therapeutic target for <i>SCN8A</i> encephalopathy. </p></section>
clinical neurology
What problem does this paper attempt to address?